KINASET THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 2B PANAIRAMA TRIAL OF FREVECITINIB (KN-002) IN PATIENTS WITH SEVERE ASTHMA

Reuters · 1d ago

Please log in to view news